Form 4: TriSalus Life Sciences CEO Buys $25,000 in Company Stock
SEC Filing Form 4
TriSalus Life Sciences CEO Mary T. Szela purchased 5,000 shares of TLSI stock at an average price of $4.97 on September 10, 2024.
Summary
- On September 10, 2024, Mary T. Szela, CEO and President of TriSalus Life Sciences, Inc. (TLSI), acquired 5,000 shares of common stock.
- The shares were purchased at a weighted average price of $4.97 per share, with individual prices ranging from $4.91 to $4.99.
- Following the transaction, Ms. Szela directly owns 369,862 shares of TriSalus Life Sciences, Inc.
- The purchase was disclosed in a Form 4 filing with the Securities and Exchange Commission on September 12, 2024.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO's stock purchase is a positive signal, but it's a relatively small transaction and doesn't provide a comprehensive view of the company's overall health.
Positives
- The CEO's purchase of company stock could be interpreted as a sign of confidence in the company's future prospects.
Industry Context
Insider buying is often seen as a positive signal, suggesting that a company's leadership believes the stock is undervalued. However, it's just one data point and should be considered alongside other factors when evaluating a company's investment potential.
Stakeholder Impact
- The stock purchase could have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 09/10/2024 | Date of stock purchase by Mary T. Szela |
| 09/12/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.